Acute Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2029

1.1 List of Tables
1.2 List of Figures

2.1 The Acute Lymphocytic Leukemia Market Will Grow at a 4.4% Rate During 2019-2029
2.2 Label Expansions and New CAR-T Cell Products Drive Improvements in Acute Lymphocytic Leukemia Care
2.3 Improved Overall Survival After Relapse and Stem Cell Transplant Replacements Remain Key Unmet Needs
2.4 CAR-T Cells Shape the Future of the Acute Lymphocytic Leukemia Market
2.5 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification and Subtypes

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used and Not Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for ALL (2019-2029)
5.5.1 Diagnosed Incident Cases of ALL
5.5.2 Age-Specific Diagnosed Incident Cases of ALL
5.5.3 Sex-Specific Diagnosed Incident Cases of ALL
5.5.4 Diagnosed Incident Cases of B-Cell and T-Cell ALL
5.5.5 Five-Year Diagnosed Prevalent Cases of ALL
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Coronavirus Disease 2019 (COVID-19) Impact
5.6.3 Limitations of the Analysis
5.6.4 Strengths of the Analysis

6.1 Overview

7.1 Overview
7.2 Agents for T-ALL and Infant ALL
7.3 More Tolerable Curative Regimens
7.4 Improving Overall Survival After Relapse
7.5 Improved CAR-T Cells and HSCT Replacements
7.6 More Convenient Regimens

8.1 Overview
8.1.1 Label Expansions in Earlier Lines of Therapy
8.1.2 Improved CAR-T Cells
8.1.3 Improved Asparaginase Products
8.2 Clinical Trials Design
8.2.1 Flexible Criteria Based on the Patient Population and Unmet Need
8.2.2 Pharmacokinetics as the Critical Endpoint for Asparaginases
8.2.3 Significant Contribution of Public Funding

9.1 Overview
9.2 Innovative Early Stage Approaches
9.3 Other Drugs in Development

10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
10.4.4 China

Table 1: Acute Lymphocytic Leukemia: Key Metrics in the 8MM
Table 2: Classification of ALL Patients
Table 3: Risk Factors and Comorbidities for ALL
Table 4: Treatment Guidelines for ALL
Table 5: Leading Treatments for ALL, 2019
Table 6: Previous ALL Pivotal Trials with Their Respective Endpoints
Table 7: Comparison of Therapeutic Classes in Development for ALL, 2019-2029
Table 8: Innovative Early Stage Approaches for ALL, 2020
Table 9: Drugs in Development for ALL, 2020
Table 10: Clinical Benchmark of Key Marketed and Pipeline Drugs - ALL
Table 11: Commercial Benchmark of Key Pipeline Drugs - ALL
Table 12: Key Events Impacting Sales for ALL in the US, 2019-2029
Table 13: ALL Market - Global Drivers and Barriers, 2019-2029
Table 14: Key Historical and Projected Launch Dates for ALL
Table 15: Key Historical and Projected Patent Expiry Dates for ALL
Table 16: Most Commonly Used Regimens for ALL in the 8MM
Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for Acute Lymphocytic Leukemia in 2019 and 2029
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Oncaspar Regimen and Blincyto
Figure 3: Comparison of Normal and Leukemia Blood Cell Differentiation
Figure 4: Agents Used to Target ALL Antigens/Pathways Specific to B- or T-cells
Figure 5: 8MM, Diagnosed Incidence of ALL, Men and Women, All Ages, 2009-2019
Figure 6: Sources Used to Forecast the Diagnosed Incident Cases of ALL
Figure 7: Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of ALL
Figure 8: 8MM, Diagnosed Incident Cases of ALL, Men and Women, All Ages, 2019
Figure 9: 8MM, Diagnosed Incident Cases of ALL by Age Group, Men and Women, 2019
Figure 10: 8MM, Diagnosed Incident Cases of ALL by Sex, All Ages, 2019
Figure 11: 8MM, Diagnosed Incident Cases of B-cell and T-Cell ALL, Men and Women, All Ages, 2019
Figure 12: 8MM, Five-Year Diagnosed Prevalent Cases of ALL, Men and Women, All Ages, 2019
Figure 13: Current Treatment Algorithm of ALL
Figure 14: Unmet Needs and Opportunities in ALL
Figure 15: Overview of the ALL Development Pipeline
Figure 16: Key Phase II/III Trials for the Promising Pipeline Agents that the Publisher Expects be Licensed for ALL in the 8MM During the Forecast Period
Figure 17: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Blincyto and Oncaspar Regimen
Figure 18: Global (8MM) Sales Forecast by Country for ALL in 2019 and 2029
Figure 19: Global Sales Forecast by Class for ALL in 2019 and 2029
Figure 20: Sales Forecast by Class for ALL in the US in 2019 and 2029
Figure 21: Sales Forecast by Class for ALL in the 5EU in 2019 and 2029
Figure 22: Sales Forecast by Class for ALL in Japan in 2019 and 2029
Figure 23: Sales Forecast by Class for ALL in China in 2019 and 2029